Inspire Medical initiated with an Outperform at Leerink

Leerink analyst Richard Newitter started Inspire Medical with an Outperform rating and $57 price target. The analyst sees it as a sustainable ultra high-growth/gross margin small-cap as the company drives higher utilization of its first and only FDA-approved neurostimulation device for obstructive sleep apnea, where current therapies have drawbacks and Inspire Medical’s unique solution can offer patient benefits over them.
https://thefly.com/landingPageNews.php?id=2812367